• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Functional analysis of oxidative stress-induced hepatocarcinogenic genes for molecular target treatment

Research Project

Project/Area Number 23590995
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Gastroenterology
Research InstitutionJikei University School of Medicine

Principal Investigator

TSUBOTA Akihito  東京慈恵会医科大学, 医学部, 教授 (90322643)

Co-Investigator(Renkei-kenkyūsha) MOGUSHI Kaoru  順天堂大学, 医学(系)研究科, 助教 (60569292)
Project Period (FY) 2011-04-28 – 2015-03-31
Project Status Completed (Fiscal Year 2014)
Budget Amount *help
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Keywords肝発癌 / 酸化ストレス / 肝腫瘍原性遺伝子 / 網羅的遺伝子発現解析 / mRNA / microRNA / siRNA / 網羅的解析
Outline of Final Research Achievements

Persistent liver injury caused by various etiology is involved in hepatocarcinogenesis, which develops through different pathways. Since the most common pathogenesis is persistent exposure to oxidative stress, oxidative stress-induced gene could be one of the most basic hepatocarcinogenic genes. IQGAP1 knockdown resulted in reduced activities of migration and invasion in some hepatoma cell lines, but not in others. Cells with high IQGAP1 expression levels were poorly-differentiated carcinomas with high migration/invasion activities. These cell properties were closely related to IQGAP1. Vimentin also played a critical role in the properties of some cell lines, indicating that knockdown of genes specific to each cancer cell is required to reduce the migration and invasion activities. Furthermore, IQGAP1 with a tumor promotion activity could have an inhibitory activity against tumor growth, suggesting that IQGAP1 has conflicting properties in a cell- and/or microRNA-dependent manner.

Report

(5 results)
  • 2014 Annual Research Report   Final Research Report ( PDF )
  • 2013 Research-status Report
  • 2012 Research-status Report
  • 2011 Research-status Report
  • Research Products

    (64 results)

All 2015 2014 2013 2012 2011

All Journal Article (35 results) (of which Peer Reviewed: 35 results,  Open Access: 1 results) Presentation (28 results) (of which Invited: 1 results) Book (1 results)

  • [Journal Article] Safety and Efficacy of Partial Splenic Embolization in Telaprevir-based Triple Therapy for Chronic Hepatitis C2015

    • Author(s)
      Kondo C, Atsukawa M, Tsubota A, Shimada N, Abe H, Itokawa N, Nakagawa A, Fukuda T, Matsushita Y, Nakatsuka K, Kawamoto C, Iwakiri K, Aizawa Y, Sakamoto C.
    • Journal Title

      Internal Medicine

      Volume: 54 Issue: 2 Pages: 119-126

    • DOI

      10.2169/internalmedicine.54.3066

    • NAID

      130004903010

    • ISSN
      0918-2918, 1349-7235
    • Related Report
      2014 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Factors associated with sustained virological response in 24-week telaprevir-based triple therapy for chronic hepatitis C genotype 1b patients with the IL28B minor genotype2015

    • Author(s)
      Abe H, Tsubota A, Shimada N, Atsukawa M, Kato K, Takaguchi K, Asano T, Chuganji Y, Sakamoto C, Toyoda H, Kumada T, Ide T, Sata M, Aizawa Y.
    • Journal Title

      Hepatol Res

      Volume: 45 Issue: 4 Pages: 387-36

    • DOI

      10.1111/hepr.12360

    • Related Report
      2014 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Relationship between HCV dynamics and sustained virological responses in chronic hepatitis C genotype 1b patients treated with telaprevir-based triple therapy2014

    • Author(s)
      Nakagawa A, Atsukawa M, Tsubota A, Shimada N, Abe H, Kondo C, Itokawa N, Arai T, Hashimoto S, Matsushita Y, Fukuda T, Nakatsuka K, Iwakiri K, Kawamoto C, Aizawa Y, Sakamoto C.
    • Journal Title

      Eur J Gastroenterol Hepatol

      Volume: 26 Issue: 12 Pages: 1329-1334

    • DOI

      10.1097/meg.0000000000000228

    • Related Report
      2014 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Predictors of response to 24-week telaprevir-based triple therapy for treatment-naïve genotype 1b chronic hepatitis C patients2014

    • Author(s)
      Abe H, Tsubota A, Shimada N, Atsukawa M, Kato K, Takaguchi K, Asano T, Chuganji Y, Sakamoto C, Toyoda H, Kumada T, Ide T, Sata M, Aizawa Y.
    • Journal Title

      Gastroenterol Res Pract

      Volume: 2014 Pages: 549709-549709

    • DOI

      10.1155/2014/549709

    • Related Report
      2014 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Pretreatment prediction of the outcome of response-guided peginterferon-α and ribavirin therapy for chronic hepatitis C2014

    • Author(s)
      Masaki N, Sugiyama M, Shimada N, Tanaka Y, Nakamuta M, Izumi N, Watanabe S, Tsubota A, Komatsu M, Masaki T, Enomoto N, Yoneda M, Murata K, Ito K, Koike K, Mizokami M.
    • Journal Title

      J Gastroenterol Hepatol

      Volume: 29 Issue: 12 Pages: 1996-2005

    • DOI

      10.1111/jgh.12646

    • Related Report
      2014 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Serum 25(OH)D3 levels affect treatment outcomes for telaprevir/peg-interferon/ribavirin combination therapy in genotype 1b chronic hepatitis C2014

    • Author(s)
      Atsukawa M, Tsubota A, Shimada N, Abe H, Kondo C, Itokawa N, Nakagawa A, Iwakiri K, Kawamoto C, Aizawa Y, Sakamoto C.
    • Journal Title

      Dig Liver Dis

      Volume: 46 Issue: 8 Pages: 738-743

    • DOI

      10.1016/j.dld.2014.05.004

    • Related Report
      2014 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides2014

    • Author(s)
      Furihata T, Matsumoto S, Fu Z, Tsubota A, Sun Y, Matsumoto S, Kobayashi K, Chiba K.
    • Journal Title

      Antimicrob Agents Chemother

      Volume: 58 Issue: 8 Pages: 4555-4564

    • DOI

      10.1128/aac.02724-14

    • Related Report
      2014 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Involvement of MAP3K8 and miR-17-5p in poor virologic response to interferon-based combination therapy for chronic hepatitis C2014

    • Author(s)
      Tsubota A, Mogushi K, Aizaki H, Miyaguchi K, Nagatsuma K, Matsudaira H, Kushida T, Furihata T, Tanaka H, Matsuura T.
    • Journal Title

      PLoS One

      Volume: 9 Issue: 5 Pages: e97078-e97078

    • DOI

      10.1371/journal.pone.0097078

    • Related Report
      2014 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Effect of fluvastatin on 24-week telaprevir-based combination therapy for hepatitis C virus genotype 1b-infected chronic hepatitis C2014

    • Author(s)
      Atsukawa M, Tsubota A, Shimada N, Kondo C, Itokawa N, Nakagawa A, Fukuda T, Matsushita Y, Narahara Y, Osada Y, Yamaguchi H, Nakatsuka K, Iwakiri K, Kawamoto C, Sakamoto C.
    • Journal Title

      Eur J Gastroenterol Hepatol

      Volume: 26 Issue: 7 Pages: 781-787

    • DOI

      10.1097/meg.0000000000000105

    • Related Report
      2014 Annual Research Report
    • Peer Reviewed
  • [Journal Article] A 48-week telaprevir-based triple combination therapy improves sustained virological response rate in previous non-responders to peginterferon and ribavirin with genotype 1b chronic hepatitis C: A multicenter study.2014

    • Author(s)
      Shimada N, Tsubota A, Atsukawa M, Abe H, Ide T, Takaguchi K, Chuganji Y, Toyoda H, Yoshizawa K, Ika M, Sato Y, Kato K, Kumada T, Sakamoto C, Aizawa Y, Sata M.
    • Journal Title

      Hepatol Res

      Volume: 2014 Mar (Epub ahead of print) Issue: 14

    • DOI

      10.1111/hepr.12323

    • Related Report
      2014 Annual Research Report 2013 Research-status Report
    • Peer Reviewed
  • [Journal Article] Serum 25-hydroxy- vitamin D3 levels affect treatment outcome in pegylated-interferon/ ribavirin combination therapy for compensated cirrhotic patients with HCV genotype 1b and high viral load.2014

    • Author(s)
      Atsukawa M, Tsubota A, Shimada N, Kondo C, Itokawa N, Nakagawa A, Hashimoto S, Fukuda T, Matsushita Y, Narahara Y, Iwakiri K, Nakatsuka K, Kawamoto C, Sakamoto C.
    • Journal Title

      Hepatol Res

      Volume: 2014 Jan (Epub ahead of print) Issue: 13 Pages: 1277-1285

    • DOI

      10.1111/hepr.12298

    • Related Report
      2014 Annual Research Report 2013 Research-status Report
    • Peer Reviewed
  • [Journal Article] Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study2014

    • Author(s)
      Shimada N, Toyoda H, Tsubota A, Ide T, Takaguchi K, Kato K, Kondoh M, Matsuyama K, Kumada T, Sata M.
    • Journal Title

      J Gastroenterol

      Volume: 49 Issue: 11 Pages: 1485-1494

    • DOI

      10.1007/s00535-013-0918-7

    • Related Report
      2014 Annual Research Report
    • Peer Reviewed
  • [Journal Article] α-Fetoprotein is a surrogate marker for predicting treatment failure in telaprevir-based triple combination therapy for genotype 1b chronic hepatitis C Japanese patients with the IL28B minor genotype.2014

    • Author(s)
      Shimada N, Tsubota A, Atsukawa M, Abe H, Ika M, Kato K, Sato Y, Kondo C, Sakamoto C, Tanaka Y, Aizawa Y.
    • Journal Title

      J Med Virol

      Volume: 86 Issue: 3 Pages: 461-472

    • DOI

      10.1002/jmv.23824

    • Related Report
      2013 Research-status Report
    • Peer Reviewed
  • [Journal Article] Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b.2014

    • Author(s)
      Tsubota A, Shimada N, Atsukawa M, Abe H, Kato K, Ika M, Matsudaira H, Nagatsuma K, Matsuura T, Aizawa Y.
    • Journal Title

      J Gastroenterol Hepatol

      Volume: 29 Issue: 1 Pages: 144-150

    • DOI

      10.1111/jgh.12402

    • Related Report
      2013 Research-status Report
    • Peer Reviewed
  • [Journal Article] Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults2014

    • Author(s)
      Ito K, Yotsuyanagi H, Yatsuhashi H, Karino Y, Takikawa Y, Saito T, Arase Y, Imazeki F, Kurosaki M, Umemura T, Ichida T, Toyoda H, Yoneda M, Mita E, Yamamoto K, Michitaka K, Maeshiro T, Tanuma J, Tanaka Y, Sugiyama M, Murata K, Masaki N, Mizokami M; Japanese AHB Study Group
    • Journal Title

      Hepatology

      Volume: 59 Issue: 1 Pages: 89-97

    • DOI

      10.1002/hep.26635

    • Related Report
      2013 Research-status Report
    • Peer Reviewed
  • [Journal Article] Hepatic stellate cells that coexpress LRAT and CRBP-1 partially contribute to portal fibrogenesis in patients with human viral hepatitis.2014

    • Author(s)
      Nagatsuma K, Hano H, Murakami K, Shindo D, Matsumoto Y, Mitobe J, Tanaka K, Saito M, Maehashi H, Owada M, Ikegami M, Tsubota A, Ohkusa T, Aizawa Y, Takagi I, Tajiri H, Matsuura T.
    • Journal Title

      Liver Int

      Volume: 34 Issue: 2 Pages: 243-252

    • DOI

      10.1111/liv.12255

    • Related Report
      2013 Research-status Report
    • Peer Reviewed
  • [Journal Article] Efficacy of alfacalcidol on PEG-IFN/ribavirin combination therapy for elderly patients with chronic hepatitis C: a pilot study.2013

    • Author(s)
      Atsukawa M, Tsubota A, Shimada N, Kondo C, Itokawa N, Nakagawa A, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Narahara Y, Nakatsuka K, Iwakiri K, Kawamoto C, Sakamoto C.
    • Journal Title

      Hepat Mon

      Volume: 13

    • Related Report
      2013 Research-status Report
    • Peer Reviewed
  • [Journal Article] Sustained and rapid virological responses in hepatitis C clinical trials.2013

    • Author(s)
      Tsubota A, Furihata T, Matsumoto Y, Chiba K.
    • Journal Title

      Clinical Investigation

      Volume: 3 Issue: 11 Pages: 1083-1093

    • DOI

      10.4155/cli.13.98

    • Related Report
      2013 Research-status Report
    • Peer Reviewed
  • [Journal Article] Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study.2013

    • Author(s)
      Shimada N, Toyoda H, Tsubota A, Ide T, Takaguchi K, Kato K, Kondoh M, Matsuyama K, Kumada T, Sata M.
    • Journal Title

      J Gastroenterol

      Volume: 2013 Nov (Epub ahead of print)

    • Related Report
      2013 Research-status Report
    • Peer Reviewed
  • [Journal Article] Serum lipoprotein profiles and response to pegylated interferon plus ribavirin combination therapy in patients with chronic HCV genotype 1b infection.2013

    • Author(s)
      Aizawa Y, Shimada N, Abe H, Seki N, Aida Y, Ishiguro H, Ika M, Kato K, Tsubota A.
    • Journal Title

      Hepat Mon

      Volume: 13 Issue: 5

    • DOI

      10.5812/hepatmon.8988

    • Related Report
      2013 Research-status Report
    • Peer Reviewed
  • [Journal Article] Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b.2013

    • Author(s)
      Yoshizawa K, Abe H, Aida Y, Ishiguro H, Ika M, Shimada N, Tsubota A, Aizawa Y.
    • Journal Title

      J Med Virol

      Volume: 85 Issue: 7 Pages: 1180-1190

    • DOI

      10.1002/jmv.23597

    • Related Report
      2013 Research-status Report
    • Peer Reviewed
  • [Journal Article] New proposal for response-guided peg-interferon-plus- ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.2013

    • Author(s)
      Abe H, Aida Y, Ishiguro H, Yoshizawa K, Seki N, Miyazaki T, Itagaki M, Sutoh S, Ika M, Kato K, Shimada N, Tsubota A, Aizawa Y.
    • Journal Title

      J Med Virol

      Volume: 85 Issue: 9 Pages: 1523-1533

    • DOI

      10.1002/jmv.23626

    • Related Report
      2013 Research-status Report
    • Peer Reviewed
  • [Journal Article] Platelet count and sustained virological response in hepatitis C treatment.2013

    • Author(s)
      Kanda T, Kato K, Tsubota A, Takada N, Nishino T, Mikami S, Miyamura T, Maruoka D, Wu S, Nakamoto S, Arai M, Fujiwara K, Imazeki F, Yokosuka O.
    • Journal Title

      World J Hepatol

      Volume: 5 Issue: 4 Pages: 182-188

    • DOI

      10.4254/wjh.v5.i4.182

    • Related Report
      2013 Research-status Report
    • Peer Reviewed
  • [Journal Article] Peginterferon Alfa-2a plus ribavirin in Japanese patients infected with hepatitis C virus genotype 2 who failed previous interferon therapy.2013

    • Author(s)
      Kanda T, Nakamoto S, Nishino T, Takada N, Tsubota A, Kato K, Miyamura T, Maruoka D, Wu S, Tanaka T, Arai M, Mikami S, Fujiwara K, Imazeki F, Yokosuka O.
    • Journal Title

      Int J Med Sci

      Volume: 10 Issue: 1 Pages: 43-49

    • DOI

      10.7150/ijms.5358

    • Related Report
      2012 Research-status Report
    • Peer Reviewed
  • [Journal Article] Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.2013

    • Author(s)
      Itokawa N, Atsukawa M, Tsubota A, Kondo C, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Narahara Y, Nakatsuka K, Kanazawa H, Iwakiri K, Sakamoto C.
    • Journal Title

      J Gastroenterol Hepatol

      Volume: 28 Issue: 3 Pages: 443-449

    • DOI

      10.1111/jgh.12039

    • Related Report
      2012 Research-status Report
    • Peer Reviewed
  • [Journal Article] Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b.2013

    • Author(s)
      Atsukawa M, Tsubota A, Kondo C, Itokawa N, Narahara Y, Nakatsuka K, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Kanazawa H, Sakamoto C.
    • Journal Title

      J Gastroenterol Hepatol

      Volume: 28 Issue: 1 Pages: 51-56

    • DOI

      10.1111/j.1440-1746.2012.07267.x

    • Related Report
      2012 Research-status Report
    • Peer Reviewed
  • [Journal Article] Several factors including ITPA polymorphism influence ribavirin-induced anemia in chronic hepatitis C.2012

    • Author(s)
      Tsubota A, Shimada N, Abe H, Yoshizawa K, Agata R, Yumoto Y, Ika M, Namiki Y, Nagatsuma K, Matsudaira H, Fujise K, Tada N, Aizawa Y.
    • Journal Title

      World J Gastroenterol

      Volume: 18 Issue: 41 Pages: 5879-5888

    • DOI

      10.3748/wjg.v18.i41.5879

    • Related Report
      2012 Research-status Report
    • Peer Reviewed
  • [Journal Article] Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1b patients.2012

    • Author(s)
      Tsubota A, Shimada N, Yoshizawa K, Furihata T, Agata R, Yumoto Y, Abe H, Ika M, Namiki Y, Chiba K, Fujise K, Tada N, Aizawa Y.
    • Journal Title

      Liver Int

      Volume: 32 Issue: 5 Pages: 826-836

    • DOI

      10.1111/j.1478-3231.2011.02727.x

    • Related Report
      2012 Research-status Report
    • Peer Reviewed
  • [Journal Article] Inorganic-Organic Magnetic Nanocomposites for use in Preventive Medicine: A Rapid and Reliable Elimination System for Cesium.2012

    • Author(s)
      Namiki Y, Namiki T, Ishii Y, Koido S, Nagase Y, Tsubota A, Tada N, Kitamoto Y.
    • Journal Title

      Pharm Res

      Volume: 29 Issue: 5 Pages: 1404-1418

    • DOI

      10.1007/s11095-011-0628-x

    • Related Report
      2012 Research-status Report
    • Peer Reviewed
  • [Journal Article] An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin.2012

    • Author(s)
      Kondo C, Atsukawa M, Tsubota A, Itokawa N, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Narahara Y, Nakatsuka K, Kanazawa H, Sakamoto C.
    • Journal Title

      J Viral Hepat

      Volume: 19 Issue: 9 Pages: 615-622

    • DOI

      10.1111/j.1365-2893.2011.01584.x

    • Related Report
      2012 Research-status Report
    • Peer Reviewed
  • [Journal Article] ENT1, a ribavirin transporter, plays a pivotal role in antiviral efficacy of ribavirin in a hepatitis C virus replication cell system2012

    • Author(s)
      Iikura M, Furihata T, Mizuguchi M, Nagai M, Ikeda M, Kato N, Tsubota A, Chiba K.
    • Journal Title

      Antimicrob Agents Chemother

      Volume: 56 Pages: 1407-13

    • Related Report
      2011 Research-status Report
    • Peer Reviewed
  • [Journal Article] Genotype rs8099917 near the IL28B gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum apolipoprotein B-100 concentration in chronic hepatitis C.2012

    • Author(s)
      Aizawa Y, Yohizawa K, Aida Y, Ishiguro H, Abe H, Tsubota A.
    • Journal Title

      Mol Cell Biochem

      Volume: 360 Pages: 9-14

    • Related Report
      2011 Research-status Report
    • Peer Reviewed
  • [Journal Article] Occurrence of hepatocellular carcinoma was not a rare event during and immediately after antiviral treatment in Japanese HCV-positive patients.2011

    • Author(s)
      Kanda T, Imazeki F, Mikami S, Kato K, Shimada N, Yonemitsu Y, Miyauchi T, Arai M, Fujiwara K, Tsubota A, Takada N, Nishino T, Takashi M, Sugiura N, Kimura M, Fukai K, Yokosuka O.
    • Journal Title

      Oncology

      Volume: 80 Pages: 366-72

    • Related Report
      2011 Research-status Report
    • Peer Reviewed
  • [Journal Article] Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients.2011

    • Author(s)
      Aizawa M, Tsubota A, Fujise K, Tatsuzawa K, Kono M, Hoshina S, Tajiri H.
    • Journal Title

      J Med Virol

      Volume: 83 Issue: 6 Pages: 953-61

    • DOI

      10.1002/jmv.22025

    • Related Report
      2011 Research-status Report
    • Peer Reviewed
  • [Journal Article] Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test.2011

    • Author(s)
      Kanda T, Imazeki F, Yonemitsu Y, Mikami S, Takada N, Nishino T, Takashi M, Tsubota A, Kato K, Tanaka T, Nakamoto S, Kurihara T, Arai M, Fujiwara K, Kanai F, Yokosuka O.
    • Journal Title

      J Viral Hepat

      Volume: 18 Issue: 7 Pages: 292-7

    • DOI

      10.1111/j.1365-2893.2010.01409.x

    • Related Report
      2011 Research-status Report
    • Peer Reviewed
  • [Presentation] Response-guided Peginterferonα+Ribavirin療法施行Genotype2型C型慢性肝炎の治療効果におけるIL28B遺伝子多型測定の意義2014

    • Author(s)
      安部 宏,石黒晴哉,島田紀朋,関 伸嘉,杉田知典,会田雄太,富田陽一,永野智久,板垣宗徳,須藤 訓,坪田昭人,相澤良夫.
    • Organizer
      第40回日本肝臓学会東部会
    • Place of Presentation
      京王プラザ(東京都新宿区)
    • Year and Date
      2014-11-27
    • Related Report
      2014 Annual Research Report
  • [Presentation] 我が国におけるC型慢性肝炎患者の血清25(OH)D3濃度の特徴2014

    • Author(s)
      中川 愛,厚川正則,島田紀朋,阿部 宏,吉澤 海,浅野 徹,大久保雄介,荒木眞裕,池上 正,糸川典夫,近藤千紗,中塚雄久,忠願寺義通,坪田昭人,相澤良夫,坂本長逸.
    • Organizer
      第40回日本肝臓学会東部会
    • Place of Presentation
      京王プラザ(東京都新宿区)
    • Year and Date
      2014-11-27
    • Related Report
      2014 Annual Research Report
  • [Presentation] C型慢性肝炎における血清25(OH)D3濃度の特徴についての検討2014

    • Author(s)
      新井泰央,厚川正則,島田紀朋,安部 宏,大久保知美,中川 愛,糸川典夫,近藤千紗,坪田昭人,相澤良夫,川本智章,坂本長逸.
    • Organizer
      第18回日本肝臓学会大会
    • Place of Presentation
      神戸国際展示場・ポートピアホテル・神戸国際会議場(兵庫県神戸市)
    • Year and Date
      2014-10-23
    • Related Report
      2014 Annual Research Report
  • [Presentation] Telaprevir3剤療法を導入したIL28B Major genotypeのC型慢性肝炎における非SVRに関与する因子の検討2014

    • Author(s)
      安部 宏,島田紀朋,厚川正則,坪田昭人,關 伸嘉,杉田知典,会田雄太,井家麻紀子,相澤良夫.
    • Organizer
      第18回日本肝臓学会大会
    • Place of Presentation
      神戸国際展示場・ポートピアホテル・神戸国際会議場(兵庫県神戸市)
    • Year and Date
      2014-10-23
    • Related Report
      2014 Annual Research Report
  • [Presentation] Simeprevir3剤併用療法におけるvitamin D併用療法の治療初期効果について2014

    • Author(s)
      厚川正則,島田紀朋,吉澤 海,安部 宏,中川 愛,糸川典夫,近藤千紗,坪田昭人,相澤良夫,坂本長逸.
    • Organizer
      第18回日本肝臓学会大会
    • Place of Presentation
      神戸国際展示場・ポートピアホテル・神戸国際会議場(兵庫県神戸市)
    • Year and Date
      2014-10-23
    • Related Report
      2014 Annual Research Report
  • [Presentation] C型慢性肝炎に対する3剤併用療法のHCV RNA陰性化時期がSVRに与える影響~48週延長投与例も含めた解析2014

    • Author(s)
      中川 愛,厚川正則,島田紀朋,安部 宏,加藤慶三,近藤千紗,糸川典夫,福田 健,松下洋子,中塚雄久,長田祐二,岩切勝彦,川本智章,坪田昭人,相澤良夫,坂本長逸.
    • Organizer
      第50回日本肝臓学会総会
    • Place of Presentation
      ホテルニューオータニ(東京都千代田区)
    • Year and Date
      2014-05-29
    • Related Report
      2014 Annual Research Report
  • [Presentation] Non-responderに対するT12PR48はSVRを向上させる2014

    • Author(s)
      島田紀朋, 厚川正則,坪田昭人.
    • Organizer
      第50回日本肝臓学会総会
    • Place of Presentation
      ホテルニューオータニ(東京都千代田区)
    • Year and Date
      2014-05-29
    • Related Report
      2014 Annual Research Report
  • [Presentation] Peg-IFN/ribavirin/telaprevir三剤併用療法における再燃に寄与する因子の検討2014

    • Author(s)
      近藤千紗,厚川正則,島田紀朋,安部 宏,中川 愛,糸川典夫,加藤慶三,福田 健,松下洋子,楢原義之,中塚雄久,岩切勝彦,川本智章,坪田昭人,相澤良夫,坂本長逸.
    • Organizer
      第50回日本肝臓学会総会
    • Place of Presentation
      ホテルニューオータニ(東京都千代田区)
    • Year and Date
      2014-05-29
    • Related Report
      2014 Annual Research Report
  • [Presentation] B型慢性肝炎に対するペグインターフェロン療法~開始直前HBe抗原からみた治療効果の検討~2014

    • Author(s)
      神田達郎,島田紀朋,厚川正則,篠崎正美,三上 繁,中本晋吾,新井誠人,今関文夫,坪田昭人,横須賀収.
    • Organizer
      第50回日本肝臓学会総会
    • Place of Presentation
      ホテルニューオータニ(東京都千代田区)
    • Year and Date
      2014-05-29
    • Related Report
      2014 Annual Research Report
  • [Presentation] C型慢性肝炎に対するTelaprevir+Peginterferon+Ribavirin3剤療法の治療成績2014

    • Author(s)
      安部 宏,島田紀朋,厚川正則,坪田昭人,關 伸嘉,杉田知典,会田雄太,加藤慶三,坂本長逸,相澤良夫.
    • Organizer
      第50回日本肝臓学会総会
    • Place of Presentation
      ホテルニューオータニ(東京都千代田区)
    • Year and Date
      2014-05-29
    • Related Report
      2014 Annual Research Report
  • [Presentation] TVR3剤併用療法の早期HCV動態から見た治療効果予測2014

    • Author(s)
      島田紀朋,高口浩一,井出達也,加藤慶三,坪田昭人,豊田秀徳,熊田 卓,佐田通夫.
    • Organizer
      第100回日本消化器病学会総会
    • Place of Presentation
      東京国際フォーラム(東京都千代田区)
    • Year and Date
      2014-04-24
    • Related Report
      2014 Annual Research Report
  • [Presentation] IL28B minor genotypeのC型慢性肝炎に対する3剤併用療法における再燃に寄与する因子の検討2014

    • Author(s)
      近藤千紗,厚川正則,島田紀朋,安部 宏,中川 愛,糸川典夫,加藤慶三,福田 健,松下洋子,楢原義之,中塚雄久,岩切勝彦,川本智章,坪田昭人,相澤良夫,坂本長逸.
    • Organizer
      第100回日本消化器病学会総会
    • Place of Presentation
      東京国際フォーラム(東京都千代田区)
    • Year and Date
      2014-04-24
    • Related Report
      2014 Annual Research Report
  • [Presentation] 代償性肝硬変に対するpeg-IFN/ribavirin併用療法に血清25(OH)D3濃度に与える影響2014

    • Author(s)
      中川 愛,厚川正則,島田紀朋,糸川典夫,近藤千紗,安良岡高志,橋本知実,福田 健,松下洋子,城所秀子,楢原義之,中塚雄久,坪田昭人,岩切勝彦,川本智章,坂本長逸.
    • Organizer
      第100回日本消化器病学会総会
    • Place of Presentation
      東京国際フォーラム(東京都千代田区)
    • Year and Date
      2014-04-24
    • Related Report
      2014 Annual Research Report
  • [Presentation] C型慢性肝炎IL28B minor genotypeに対するAlfacalcidol併用3剤療法についての検討;Pilot Study2014

    • Author(s)
      糸川典夫,厚川正則,坪田昭人,近藤千紗,橋本知美,松下洋子,福田 健,城所秀子,楢原義之,中塚雄久,金沢秀典,坂本長逸.
    • Organizer
      第100回日本消化器病学会総会
    • Place of Presentation
      東京国際フォーラム(東京都千代田区)
    • Year and Date
      2014-04-24
    • Related Report
      2014 Annual Research Report
  • [Presentation] C型慢性肝炎Naïve症例に対するTelaprevir+Peginterferon+Ribavirin3剤療法の治療成績2014

    • Author(s)
      安部 宏,島田紀朋,厚川正則,加藤慶三,坪田昭人,坂本長逸,相澤良夫.
    • Organizer
      第100回日本消化器病学会総会
    • Place of Presentation
      東京国際フォーラム(東京都千代田区)
    • Year and Date
      2014-04-24
    • Related Report
      2014 Annual Research Report
  • [Presentation] Bovine lactoferrinの酸化ストレス状態における効果と作用機序 ~ラクトフェリンのこれから~2014

    • Author(s)
      坪田昭人
    • Organizer
      第4回臨床ラクトフェリンシンポジウム
    • Place of Presentation
      昭和大学-旗の台キャンパス(東京都品川区)
    • Year and Date
      2014-04-09
    • Related Report
      2014 Annual Research Report
    • Invited
  • [Presentation] 早期ウイルス動態からのTelaprevir3剤併用療法の治療効果予測の検討.2013

    • Author(s)
      加藤慶三,島田紀朋,豊田秀徳,井出達也,坪田昭人,高口浩一,佐田通夫,泉 並木,熊田 卓
    • Organizer
      第17回日本肝臓学会大会
    • Place of Presentation
      グランドホテル高輪・新高輪(東京都港区)
    • Related Report
      2013 Research-status Report
  • [Presentation] 脾腫を伴う血小板低値のC型慢性肝炎に対するPSE先行3剤併用療法の検討.2013

    • Author(s)
      厚川正則,島田紀朋,坪田昭人,近藤千紗,糸川典夫,中川 愛,福田 健,楢原義之,安部 宏,相澤良夫,岩切勝彦,坂本長逸.
    • Organizer
      第17回日本肝臓学会大会
    • Place of Presentation
      グランドホテル高輪・新高輪(東京都港区)
    • Related Report
      2013 Research-status Report
  • [Presentation] 血清アポリポプロテインE(apoE)値はHCV持続感染の病態に関与するか?2013

    • Author(s)
      相澤良夫,安部 宏,關 伸嘉,会田雄太,石黒晴哉,,島田紀行朋,坪田昭人.
    • Organizer
      第17回日本肝臓学会大会
    • Place of Presentation
      グランドホテル高輪・新高輪(東京都港区)
    • Related Report
      2013 Research-status Report
  • [Presentation] C型慢性肝炎に対するTelaprevirを含む3剤併用療法における治療成績2013

    • Author(s)
      中川 愛,厚川正則,島田紀朋,坪田昭人,糸川典夫,近藤千紗,福田 健,松下洋子,楢原義之,中塚雄久,長田祐二,岩切勝彦,坂本長逸.
    • Organizer
      第17回日本肝臓学会大会
    • Place of Presentation
      グランドホテル高輪・新高輪(東京都港区)
    • Related Report
      2013 Research-status Report
  • [Presentation] IL28B gene and very early viral kinetics (Week-1) predict sustained virological response to triple therapy in chronic hepatitis C patients with genotype 1b and high viral load.2013

    • Author(s)
      Ide T, Sata M, Takaguchi K, Toyoda H, Kumada T, Shimada N, Kato K, Tsubota A, Izumi N.
    • Organizer
      The Liver Meeting, The 64th Annual Meeting of the AASLD 2013
    • Place of Presentation
      Washington, DC, USA
    • Related Report
      2013 Research-status Report
  • [Presentation] IL28BゲノタイプおよびHCV G1bコア70番アミノ酸置換から見たテラプレビル,リバビリン,ペグインターフェロン3剤併用療法の治療効果の検討.2013

    • Author(s)
      安部 宏,島田紀朋,厚川正則,坪田昭人,関 伸嘉,会田雄太,石黒晴哉,井家麻紀子,加藤慶三,相澤良夫.
    • Organizer
      第49回日本肝臓学会総会
    • Place of Presentation
      京王プラザホテル(東京都新宿区)
    • Related Report
      2013 Research-status Report
  • [Presentation] 早期ウイルス動態からのTelaprevir 3剤併用療法の治療効果予測の検討.2013

    • Author(s)
      加藤慶三,RGT研究会(坪田昭人).
    • Organizer
      第49回日本肝臓学会総会
    • Place of Presentation
      京王プラザホテル(東京都新宿区)
    • Related Report
      2013 Research-status Report
  • [Presentation] TVR3剤併用療法のウイルス陰性化時期別の治療成績の検討.2013

    • Author(s)
      島田紀朋,厚川正則,坪田昭人,安部 宏,加藤慶三,井家麻紀子,佐藤祥之,立花浩幸,米澤 健,戸田剛太郎,相澤良夫.
    • Organizer
      第49回日本肝臓学会総会
    • Place of Presentation
      京王プラザホテル(東京都新宿区)
    • Related Report
      2013 Research-status Report
  • [Presentation] C型慢性肝炎に対する3剤併用療法の治療効果に寄与する因子~スタチン併用も含め~.2013

    • Author(s)
      中川 愛,厚川正則,島田紀朋,坪田昭人,近藤千紗,糸川典夫,福田 健,松下洋子,楢原義之,長田祐二,中塚雄久,岩切勝彦,坂本長逸.
    • Organizer
      第49回日本肝臓学会総会
    • Place of Presentation
      京王プラザホテル(東京都新宿区)
    • Related Report
      2013 Research-status Report
  • [Presentation] 血小板数低値のC型慢性肝炎に対するPSE先行3剤併用療法について.2013

    • Author(s)
      近藤千紗,厚川正則,島田紀朋,坪田昭人,糸川典夫,中川 愛,橋本知実,福田 健,松下洋子,城所秀子,楢原義之,中塚雄久,金沢秀典,岩切勝彦,坂本長逸.
    • Organizer
      第49回日本肝臓学会総会
    • Place of Presentation
      京王プラザホテル(東京都新宿区)
    • Related Report
      2013 Research-status Report
  • [Presentation] C型慢性肝炎Genotype2に対する治療効果とIL28B遺伝子多型との関連性.2013

    • Author(s)
      石黒晴哉,関 伸嘉,会田雄太,安部 宏,井家麻紀子,加藤慶三,島田紀朋,坪田昭人,相澤良夫.
    • Organizer
      第49回日本肝臓学会総会
    • Place of Presentation
      京王プラザホテル(東京都新宿区)
    • Related Report
      2013 Research-status Report
  • [Presentation] B型慢性肝炎に対するPeginterferon alfa-2a単独およびSequential Therapy施行時のHBs抗原量の推移に関する検討~多施設共同研究~.2013

    • Author(s)
      神田達郎,厚川正則,島田紀朋,篠崎正美,三上繁,星野容子,加藤慶三,中本晋吾,千葉哲博,新井誠人,今関文夫,坪田昭人,横須賀収.
    • Organizer
      第49回日本肝臓学会総会
    • Place of Presentation
      京王プラザホテル(東京都新宿区)
    • Related Report
      2013 Research-status Report
  • [Book] Management of Gastric Cancer: Chapter 42011

    • Author(s)
      Tsubota A, Koyama T, Namiki Y, Tada N, Takahashi H.
    • Total Pages
      16
    • Publisher
      InTech Open Access Publisher
    • Related Report
      2011 Research-status Report

URL: 

Published: 2011-08-05   Modified: 2019-07-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi